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Abstract
BACKGROUND AND PURPOSE: Prostate cancer is the second leading cause of
cancer deaths among men in the United States. Metastasis plays a major role in patient
prognosis and treatment options. One of the factors that influences metastasis is the
activation of the c-Met signaling pathway. Activation of the growth factor c-Met results
in cytoskeletal rearrangement, migration, and invasion. Previous studies have shown
CD82 to act as an active metastatic suppressor in normal, healthy cells and is
downregulated in various forms of cancer. When CD82 is re-expressed in cancer cells,
the cells no longer express metastatic characteristics. The purpose of this study was to
determine what effect, if any, re-expression of CD82 in prostate cancer cells had on cMet mediated migratory characteristics. METHODS AND MATERIALS: Two prostate
cancer cell lines were utilized for this project. PC3-29 cells have been engineered with a
vector that expresses CD82 and PC3-5V carry an empty vector and were used as a
control in this study. ANALYSES: Expression levels of CD82, c-Met, related migratory
proteins, and the activation state of c-Met were determined via western blot analysis.
Visualization of cytoskeletal changes was done by staining F-actin fibers and focal
adhesions. RESULTS: Re-expression of CD82 in PC3-29 cells led to a decrease in c-Met
activation. CD82 prevented the formation of F-actin fibers and focal adhesions needed
for metastasis. CONCLUSIONS: CD82 directly impacts the activation of c-Met by
preventing the phosphorylation of Rac1, inhibiting the cytoskeletal changes needed for
metastasis to occur.
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Chapter One: Introduction
Prostate cancer is the second leading cause of cancer deaths among men in the
United States (1). The traditional treatments for prostate cancer are castration and
androgen-ablative therapies (2). Prostate cancer cases can be divided into two categories:
typical and non-typical. Typical prostate cancer over-expresses androgen receptors and
prostate specific antigen (PSA).
Therapeutics for prostate cancer
have taken advantage of these two
targets, but, recently research has
found that the use of androgenablative therapies and related
chemotherapies can lead to
resistance in recurrent prostate
cancer cases (2). Non-typical
prostate cancer cases do not express
androgen receptors nor PSA,
significantly limiting treatment
options. This expanding need for
new drug targets for prostate cancer
treatment has spawned hundreds of

Figure 1: Outline of the c-Met signaling pathway. c-Met
has been shown to have one endogenous ligand, HGF.
The docking of HGF to the c-Met receptor on the cell
surface signals a multitude of cellular activities that aid
in the development of metastatic characteristics.
Modified from Sridhar and Miranti, 2006.

research studies into this disease.
The rate at which a malignant tumor begins to spread, or metastasize, has a direct
impact on patient prognosis. A localized tumor has better treatment options than one that
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has metastasized to other areas of the body. One of the factors that has been shown to
lead to metastasis is the activation of the c-Met signaling pathway. The c-Met pathway
has been implicated in many cellular activities, including metastasis (Figure 1) (3).
Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. HGF
has been shown to promote the invasiveness of cancer cells by increasing matrix
adhesion and encouraging the migration of tumor cells (4). The basement membrane is a
thin, fibrous barrier separating the endothelium from the connective tissue underneath.
Once cancer cells have broken through this membrane, they are able to spread to the
nearest lymph node. The lymphatic system will give the cells direct access to the
bloodstream. -Met signaling can also be activated by engaging integrins. Integrins allow
the cell to respond to rapidly changing conditions in the cellular environment. An
elevation in integrin levels has been associated with tumorgenesis and metastasis (5).
Activation of c-Met results in the phosphorylation of four separate sites within the cell.
In addition to integrins, the absence or reduction of tumor suppressor proteins also
play a major role in the promotion of tumorigenesis. Previous studies have shown the
tumor suppressor protein CD82 to be an active metastasis suppressor in normal, healthy
cells (5). The downregulation of CD82 has been confirmed in metastatic tumors,
indicating that the protein may play a role in the suppression of metastatic signaling (5).
Cells that express physiological levels of CD82 show an overall decrease in migratory
behavior (5). CD82’s ability to interact with c-Met opens an entirely new area of
research into c-Met and its metastatic signaling cascade. A better understanding of the
mechanisms behind prostate cancer metastasis would be invaluable to developing new
treatments for castration-resistant and non-typical prostate cancer.
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Incidence, Detection, and Treatment of Prostate Cancer
In the year 2013, the most recent data available from the Centers for Disease
Control and Prevention, a total of 176,450 men were diagnosed with prostate cancer in
the United States (6). Of those men diagnosed, 27,681 died from prostate cancer in that
same year (6). The incidence of prostate cancer is steadily rising worldwide, necessitating
the need for more research into this particular form of malignancy (7). A better
understanding of the risk factors and pathology of this disease is important for developing
better treatments.
The risk factors that can lead to an increased chance of developing prostate cancer
are varied. One of the most important risk factors is age. It is estimated that only 25% of
prostate cancer cases will be diagnosed before the age of 75. Of all the different types of
cancer, prostate cancer has been shown to have the steepest age-incidence curve (7).
There also appears to be a genetic component in prostate cancer cases, as individuals who
have a first-degree relative diagnosed with the disease have a higher risk of developing
prostate cancer (7). Other risk factors include exposure to radiation, recurring urinary
tract infections, and a history of smoking (7).
Currently, there are two methods of detecting prostate cancer that have gained
clinical acceptance: PSA screening and rectal examinations. The 1980’s saw a rise in
prostate cancer diagnosis as the clinical world was introduced to the prostate-specific
antigen screening (PSA) (8). PSA is a protein produced in the prostate glands and
elevated levels of this protein have been linked to the development of prostate cancer.
PSA has been used to aid in the diagnosis of prostate cancer and patient prognosis
because of this relationship. Recently, the value of using prostate specific antigen as a
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method for detecting the presence of cancer has been called into question. The
development of the PSA screening test in the mid-1980’s led to an increase in the
reported number of prostate cancer cases; better diagnostic tools generally lead to more
cases of a disease being discovered. A study conducted in 2002 revealed that, per a
computer model of incidence rates, approximately 29% of prostate cancer diagnosis
among white males and 44% among black males were not clinically significant (9).
Treating low grade prostate cancer with high grade chemotherapy can lead to resistance
over time. Research studies conducted among original tissue samples taken from patients
in the 1980’s revealed that most of the cases diagnosed were not clinically significant,
highlighting the lack of specificity in PSA screening (9).
The sensitivity of the PSA screening test can be improved. PSA levels can predict
patient prognosis in 25% of all differentiated cancers when used in combination with the
Gleason histological diagnosis method (10). Approximately 50% of the men diagnosed
with prostate cancer will find that the cancer has metastasized beyond its tissue of origin
(10). These statistics demonstrate the need for more specific detection methods of
prostate cancer, which can only be achieved through more intensive research.

Cellular and Molecular Pathology of Prostate Cancer
Carcinogenesis is the transition of a benign tumor to a malignant one. It is an
important step in the progression of prostate cancer that has yet to be fully understood.
Research has provided significant evidence to suggest that carcinogenesis involves major
genetic changes within the once-healthy tissue, including the activation of oncogenes and
the loss of tumor suppressor genes (11).
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There are three distinct phenotypes currently associated with the transition of
normal prostate tissue to prostate cancer (11). The first is the secretory luminal cells in
the prostate epithelial tissue beginning to express prostate specific antigen (PSA), as well
as cytokeratins 8 and 18 (12, 13, 14, 15). PSA is a serine protease produced by prostate
epithelial cells and its production is regulated by the male hormone androgen (8). The
second most important phenotype is that the basal cells, which function to connect the
epithelial tissue to the stroma, begin to express cytokeratins with high molecular weights
(12) (8). Cytokeratins are proteins made up of keratin filaments found in the
cytoskeletons of epithelial cells (13). The final phenotype is when the neuroendocrine
cells, responsible for secreting products that may promote cell growth, begin to
differentiate (8). The development of these phenotypes result in a decline in cellular
division in the basal cell layer and an increase in the proliferation of the luminal secretory
cells (8). These changes that occur prior to a cell acquiring a diseased phenotype are
referred to as “premalignant proliferation disorders” and have been associated with the
abnormal expression of both tumor suppressor genes and oncogenes (8).

Genetic Factors Influencing Metastatic Characteristics
Metastasis is possibly the deadliest characteristic that a malignant tumor can
acquire. Once a tumor has penetrated the barrier that separates the tissue from the blood
supply, the cancer is free to travel throughout the entire body. It is imperative that more
research efforts into better understanding the mechanisms behind the transition to cancer
cells and the conversion of a primary tumor to a metastatic one. As mentioned before, the
metastatic status of prostate cancer plays a major role in patient prognosis, as well as in
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the selection of an appropriate treatment method. The metastatic status of the cancer
hinders treatment efficacy.
Cancer is a condition in which cell populations disregard mitotic signaling and
rapidly begin to divide. Within a cell’s genetic code are the instructions for cellular
division, for which there are checkpoints a cell must meet before it divides by a process
known as mitosis. These checkpoints ensure that the cell has doubled all genetic material,
organelles, and other cellular resources so the process of mitosis results in two complete,
healthy cells. When a cell transitions into a cancerous cell it begins to reproduce at such a
rate as to outcompete all the normal cells in the surrounding tissue. The accumulation of
these cancerous cells in one place leads to the development of a malignant tumor. The
scientific community now recognizes that cancer arises when there are mutations in one
of two sets of genes: proto-oncogenes and tumor suppressors. Proto-oncogenes are genes
that have the potential to protect cells from apoptosis, or controlled cell death. Alterations
in proto-oncogenes that lead to their activation include gene amplification,
overexpression, and other types of mutations (14). Tumor suppressors genes prevent
tumor formation. These genes become inactive when a mutation occurs in both alleles
(14). CD82 is a tumor suppressor that has been demonstrated to be downregulated in
prostate cancer (5).
Growth factor receptors also aid in the development of metastatic characteristics
in advanced cancers. Similar to proto-oncogenes, these receptors are responsible for
regulating cell growth and division. The overexpression of growth factor receptors has
been observed in multiple types of cancer, including prostate cancer. c-Met is a growth
factor receptor that has been demonstrated to have an impact in the transition from a
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localized tumor cell to a metastatic tumor. The study described in this manuscript had the
goal of determining the way in which the tumor suppressor CD82 interacts with the cell
signaling mediated cascade by the growth factor receptor known as c-Met.

Progression from Localized Tumor to Bone Metastasis in Prostate Cancer
The degree to which a prostate cancer tumor has metastasized is directly
proportional to the expected survival rate of that patient. Patients with a localized tumor
have a five-year survival rate of approximately 100%; for those with a metastatic
phenotype, the five-year survival rate can drop to as low as 31% (15). While prostate
cancer is able to metastasize to any other tissue type in the body, it demonstrates a
proclivity towards invading the bone (15). The location of the prostate gland in the male
pelvic region provides an environment rich in bone to metastasize to. One of the
hallmarks of prostate cancer development is its dependence on stimulation via the
secretion of androgen. Androgen binds to the receptor found in the cytoplasm; upon
activation, the receptor will then translocate into the nucleus (15). Once the complex has
entered the nucleus, it will go on to influence the transcription of androgen-related genes
and the proliferation of the prostate cancer cells (15).
The dependence of prostate cancer on the secretion of androgen has led to
castration serving as the most common treatment option (15). While surgical castration
can be performed, chemical castration is a temporary alternative; patients are treated with
antiandrogen drugs that function to either prevent androgen from being secreted or
prevent androgen from binding to its receptor. The effectiveness of castration on early
metastatic prostate cancer is limited, as the disease will eventually adapt to the new
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chemical environment and become “castration resistant” (15). One hypothesis behind this
phenomenon is that the tumor gradually becomes hypersensitive to androgen stimulation,
lowering the stimulation threshold so that it will take less androgen to elicit the same
initial response (15). Another possibility is that the tumor adapts in such a way that both
the autocrine and paracrine production of androgen is upregulated in order to compensate
for the effects of castration (15). The androgen receptor could also be adapting to the lack
of androgen by becoming activated via other steroids, such as estrogens, and ligandindependent activation by tyrosine kinases (15).
The metastasis of prostate cancer is a complex, multistep process in which a
tumor cell will leave its tissue of origin and spread to a secondary tumor site (15). The
first step of the metastatic process is decreased cell adhesion, which is characterized by a
shift from epithelial to mesenchymal tissue (15). This phenomenon is known as the
epithelial to mesenchymal transition (EMT), and is when epithelial cells begin to take on
the properties of mesenchymal stem cells. While EMT has yet to be fully understood, one
of the hallmark traits is cadherin switching (15). Normal epithelial cells express a large
amount of E-cadherin. During cadherin switching, the production of E-cadherin is
downregulated, and expression of N-cadherin is upregulated to levels normally associated
with mesenchymal stem cells (15). There is also an association between decreased Ecadherin expression and decreased β-cadherin expression, both of which have been linked
to more aggressive cases of prostate cancer (15). In vitro model system studies have
proven that the levels of E-cadherin are significantly reduced in more invasive human
prostate cancer cell lines (15).
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When a cell has undergone EMT, there is a noticeable decrease in cell adhesion
that is observed. The second step in metastasis is the cells demonstrating mesenchymal
properties begin to detach from the primary tumor site. It is critical that normal cells
become anchored to their environment, as forming cell junctions with adjacent cells is
needed for adequate cell-to-cell communication. For cancer cells, the dependence on
physical stability is not as crucial. Normal prostate epithelial cells are limited in their
ability to migrate, as the basal layer of cells is attached to the lumen, which in turn is
attached to the basement membrane (15). Metastasis is characterized by decreased cell
adhesion; early metastatic prostate cancer cells have been shown to have altered
expression of molecules that are critical to cell adhesion, such as E-cadherin (15). Ecadherin is a cell adhesion molecule (CAM) that serves to form an anchor between cells
and also works with β-cadherin to hold the actin cytoskeleton in place (15).
Integrins also play a role in the decreased cell attachment observed in the initial
stages of metastatic prostate cancer. These signaling molecules are responsible for
regulating cellular processes such as cell survival, cell motility, and cell migration by
associating with focal adhesions (15). The principle integrins found in normal prostate
epithelial cells are α5β1, α6β1, and α6β4, along with slightly lower expression of αvβ3
and α3β1 (15). There is a correlation between the reduced expression of α6 and the
invasiveness of prostate tumor biopsy samples that has been experimentally demonstrated
(15). The reduced expression of these critical integrins results in a decrease in cell
adhesion which further stimulates metastasis in malignant tumors (15).
Signaling through focal adhesions, (macromolecular assemblies that transmit
regulatory signals), can also be accomplished by nonreceptor tyrosine kinase focal
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adhesion kinase (FAK) and the Src family of kinases (15). When a cell is preparing to
migrate, focal adhesions are assembled at the edges of the cell and form structures that
are known as lamellipodia, allowing the cell to anchor itself to the extracellular matrix
(ECM) to pull itself along the tissue. Once the cell has finished contacting, the focal
adhesions will disassemble and then re-form for the next movement (15). Studies have
shown that the inhibition of FAK has a significant effect on a cell’s ability to migrate,
including changes in integrin concentrations (15). PC3 cells a correlation between high
levels of FAK expression and an increase in the development of metastatic characteristics
(15). After integrins associate with FAK, the phosphorylation of FAK leads to the
phosphorylation of Src (15). The Src family of kinases stimulates cell migration via the
phosphorylation of the E-cadherin/β-cadherin complex (Figure 2). The Src family of
kinases has been shown to be activated by several different mechanisms, including the
growth factor receptors. Phosphoinositide 3-kinase (P13K) is part of a family of signal
transduction enzymes that is responsible for activating β-catenin.
Prostate cancer cells can migrate in part due to the partial degradation of the ECM
by molecules known as proteinases (15). The major proteinases that are involved in the
degradation process associated with the migration of prostate cancer cells are matrix
metalloproteinases (MMPs) and serine proteinases (15). MMPs are a family of
proenzymes that bind to zinc and remain activated until proteolytic cleavage occurs (15).
ProMMP-2 is activated by Type 1 MMP, which then activates MMP-2 and MMP-9 (15).
Compared to normal levels found in prostate epithelial cells, metastatic prostate cancer
cells have a higher ratio of MMP-2/-9 to tissue inhibitor of metalloproteinases-1 (TIMP-
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1) (15). Similar elevated ratios have been correlated with higher scoring tumors on the
Gleason scale, and thus is also associated with a higher patient fatality rate (15).
When the ECM has finally degraded sufficiently to allow the malignant cells to
infiltrate the circulatory system, they must remain in circulation long enough to attach to
the vascular endothelium (15). The prostate cancer cells must then interact with the
surrounding tissue to leave the blood vessel and enter the bone, which is one of the most
poorly understood aspects of prostate cancer metastasis (15). As mentioned before,
prostate cancer displays a high affinity for metastasizing to bone tissue (15). One aspect
of the binding of metastatic prostate cancer to the bone is that the endothelial tissue
within the bone is constitutively expressing adhesion molecules, such as P-selectin (15).
P-selectin is a transmembrane protein that is commonly expressed in both endothelial
tissue and platelets. Specifically, it is found in Weibel-Palade bodies in endothelial tissue
and in the alpha granules in platelets (16). When the appropriate cells are stimulated, Pselectin is translocated to the plasma membrane (16).
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Figure 2: Graphical representation of the Src stimulation of metastatic invasion via the phosphorylation of the Ecadherin/β-catenin complex. When the E-cadherin molecule is phosphorylated, it forms a complex with βcatenin. The Src protein is then activated, and the complex is able to interact with the actin cytoskeleton. Adapted
from Jin, et al. (2011) (15)

Somatic Mutations Contributing to the Metastatic Phenotype in Castration
Resistant Prostate Cancer
Molecular biomarkers are objective characteristics that indicate a diseased
phenotype, even if the patient is not yet presenting symptoms. In terms of prostate cancer,
molecular biomarkers would improve patient prognosis by providing physicians with the
means of distinguishing between aggressive subtypes and identifying metastasis early on.
A twin study published in 2009 estimates that approximately 42% of disease disparity
can be linked to genetic variation, some of which are linked to somatic alterations (17).
Insufficient data regarding a metastatic phenotype is partially due to the heterogeneity of
primary prostate tumors (18). Prostate cancer tumors are often made up of many
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genetically distinct layers that make it difficult to identify the actual mutations that led to
the cancer cells migrating from their tissue of origin.
There is also substantial evidence to support the association between somatic
mutations and the development of hormone-related cancers. One of the most well-known
associations is between specific mutations in the BRCA1 and BRCA2 genes and the
development of breast cancer. A study published in 2013 found that exomes of metastatic
prostate cancer tumors contained an Ashkenazi Jewish germline mutation del185AG in
BRCA1 (18). The BRCA1 gene is located on the seventeenth chromosome; the germline
mutation del185AG indicates a 185 deletion of AG (19). Specifically the BRCA1 gene is
responsible for the regulation of the cell cycle and DNA repair (19). In addition to the
del185AG germline mutation, researchers found sixty-two somatic alterations in proteins,
some of which were products of cancer related genes (18). The cancer related genes
found to have genetic variants amongst the prostate cancer tumor samples were
TMPRSS2-ERG, TET2, and PBRM1 (18). The majority of the alterations were present in
only the metastatic prostate cancer tumor samples, with a smaller group of alterations
being specific to primary tumors only (18).

CD82/KAI1 Protein as a Metastasis/Tumor Suppressor
The metastatic suppressor CD82 was first characterized by Dong, et al. in 1995
(20). Microcell-mediated chromosome transfer revealed the location of the gene to be
11p11.2-13 and was later confirmed using Southern blot analysis (20). The four-domain
structure of CD82 places it in the tetraspanin superfamily (21). Tetraspanins have been
found only in multi-cellular organisms and are expressed at relatively similar levels in all
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organisms in which they are present (21). While CD82 does not appear to have any
function by itself, it has been found to associate with other proteins and regulate their
functions. The down-regulation of CD82 has been linked to tumor metastasis and poor
patient prognosis. Studies have shown that the loss of CD82 expression has been
implicated in approximately 70% of all prostate cancer cases (7).
One of the mechanisms by which CD82 controls metastasis is by influencing
cellular adhesion. A study published in 2015 demonstrated that the expression levels of
CD82 play a role in inhibiting both metastasis and invasion in primary tumor cells (22).
When malignant tumor cells were modified to over-express CD82, researchers found that
the cells over-expressing the CD82 protein adhered more strongly to the endogenous
matrix, and the ability of the cells to adhere to the endothelium tissue of blood vessels
was greatly diminished (22). The over-expression of CD82 inhibits a tumor cell’s ability
to invade other tissues by influencing cellular adherence to the tissue of origin (22). This
means that when CD82 is over-expressed in tumor cells they are firmly adhered to the
surrounding tissue, and the probability of the tumor metastasizing is very low. CD82
expression is up-regulated by the cellular tumor antigen p53, the proto-oncogene junB,
and the transcription factor known as AP2 (5). The over-expression of CD82 also
prevents tumor cells from adhering to the walls of blood vessels. It should be noted here
that while CD82 does inhibit tumor metastasis, it does not interfere with primary tumor
formation (5). CD82 interferes with a primary tumor’s ability to invade and migrate to
non-native tissues (5). What is currently not known is the mechanism by which CD82 can
suppress tumor cell invasion and metastasis.
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Regulation of Growth Factor Receptor c-Met by CD82
CD82 regulates cellular activities by associating with proteins from its location in
the cellular membrane. One of the proteins that CD82 has been found to associate with
the growth factor receptor known as c-Met (23). Growth factors are proteins that are
responsible for maintaining the growth and development of cells by regulating intracellular activity via a biological phenomenon known as a signaling cascade. c-Met is a
growth factor receptor that is found within the cellular membrane in all cells, whether it
be cancerous or healthy. The only known ligand that binds to c-Met is hepatocyte growth
factor (HGF). When HGF docks at the binding site located on the α subunit of the c-Met
protein, the protein is activated. Activation of the c-Met protein results in the
phosphorylation of four key sites: pY1003, pY1234/1235, pY1349, and pY1356. The
phosphorylation of these sites recruits specific downstream molecules that lead to
downstream signaling events, such as cell survival, cell proliferation, cytoskeletal
rearrangement, cell adhesion, invasion, and migration (Figure 1).
The c-Met receptor can also be activated by integrin crosstalk within the
cytoplasm. Integrins are small signaling molecules that facilitate a connection between
the extracellular matrix and intra-cellular structures, such as the cytoskeleton (23). The
interaction between integrins results in the phosphorylation of the c-Met phosphorylation
sites and the signaling cascade begins. Several studies have reported a change in integrin
levels within cancerous tissues, with prostate cancer cells showing elevated levels of
α3β1 and α6β1 (23). These integrins have been shown to regulate the same cellular
activities as c-Met, further implicating them in regulating cell migration and metastasis
(5).
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Research into c-Met has yet to reveal the specific ways in which CD82 interferes
with the c-Met signaling cascade and its related downstream molecules. An experiment
conducted by Sridhar and Miranti in 2006 provided significant insight into the regulatory
action of CD82 on the c-Met signaling pathway. Using the prostate cancer cell line PC3,
researchers performed a series of experiments to test the hypothesis that CD82 regulates
the integrin-mediated activation of the c-Met pathway (5). They chose a metastatic
prostate cancer model, as c-Met has been shown to be highly over-expressed in prostate
cancer and has been linked to chemotherapy resistance. One of the study’s major findings
was that CD82 does not regulate the actual expression of c-Met. After CD82 was reintroduced into the metastatic prostate cancer cells, western blots showed that there was
the same concentration of c-Met protein in both the experimental cells and the controls
(5). However, when the activation levels of c-Met were tested, there was a definite
difference between the two cell lines. The cells that were expressing CD82 showed
markedly reduced levels of activated c-Met, while the levels of activated c-Met in control
cells remained high (5). Even though c-Met is still being produced at the same rate within
the cancerous tissues, the re-expression of CD82 appears to prevent c-Met from being
activated (5).
Having concluded that CD82 expression was interfering with the activation of the
c-Met signaling pathway, the next step was to investigate the mode of inhibition. The first
hypothesis was that CD82 and c-Met were physically interacting with one another due to
their respective locations on the cell surface. When immunostaining was carried out on
CD82-expressing cells, it was discovered that this was not the case. While CD82 and cMet are located near one another, there is no co-localization between the two proteins
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that would result in the de-activation of c-Met (5). This further supported the authors’
hypothesis that CD82 was interfering with the integrin crosstalk responsible for c-Met
activation within the cytoplasm.
After immunostaining ruled out the possibility of co-localization between the two
proteins, the authors then tested the hypothesis of an indirect deactivation mechanism. cMet is responsible for the regulation of many cellular activities and it does so by the
activation of downstream signaling molecules. One of these molecules is Src, a nonreceptor kinase that is known to transform healthy cells into malignant tumors when
overexpressed (24). When HGF binds to c-Met, or c-Met is activated by integrin
crosstalk, the phosphorylation of pY1349 leads to the activation of Src (23). Higher
expression of Src and its downstream signaling partners have been demonstrated to be
overexpressed in a variety of cancers, including breast cancer, pancreatic cancer, and
prostate cancer (24). In the c-Met signaling pathway, Src substrates include focal
adhesion kinase (FAK) and p130 Crk associated substrate (p130Cas). Fibroblasts from
FAK-null mice demonstrate decreased migration behavior, but an increase in local
adhesions to the surrounding cytoskeleton (25). Migration and invasion of tumor cells
require an elaborate rearrangement of the cytoskeleton to form the lamellipodi (a
cytoskeletal projection made of actin filaments), necessary for cell movement. The
construction and maintenance of this actin fiber scaffolding is carried out through the
formation of focal adhesions, a task in which FAK plays a critical role. The FAK-Src
complex is then responsible for the phosphorylation of paxillin, and p130Cas (25). Both
molecules mediate the organization of focal adhesions and the cytoskeleton, which
ultimately allow the cell to migrate (25). Similar to the FAK-null mice, mice lacking
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p130Cas demonstrated poor actin filament arrangement and decreased migration
behavior (25).
Given the similarities between FAK-null mice and PC3 cells re-expressing CD82,
the possibility that CD82 was interfering with Src activation was explored. Using
western-blotting analysis, CD82 was found to regulate the phosphorylation of Src and
subsequently the activation of FAK and p130Cas (24). The presence of the CD82 protein
was linked to the inhibition of the tyrosine phosphorylation associated with p130Cas
(24). When CD82 is present, there is a reduction in the integrin mediated activation of
Src and related proteins, most likely contributing to the lack of migration seen in CD82
expressing tumors. Keeping in mind that the inhibition of c-Met also blocks invasion, the
conclusion can be reached that CD82 expression reduces the invasive phenotype through
the reduction of both c-Met and Src signaling (24).

Oncogenic c-Met Signaling and Tumor Development
The identification of c-Met as an oncogenic target originated from the discovery
of a missense c-Met mutation in patients who had been diagnosed with hereditary
papillary renal cell carcinomas (PRCCs) (26). These mutations include trisomy of
chromosome 7, which has been identified as a common mutation in PRCC patients (27)
(28). Somatic mutations of c-Met have been identified in a variety of cancers, including
gastric, head and neck, liver, ovarian, and thyroid (29). Elevated levels of the c-Met
ligand HGF lead to the over-activation of the c-Met signaling pathway. In addition to
somatic mutations in c-Met being linked to cancer development, somatic mutations in
HGF have also been identified in a variety of different cancers (29). One of the most
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common mutations in HGF is in the promoter region of the HGF gene, resulting in the
increased expression of HGF and the over-activation of the c-Met pathway (30). A study
conducted by Ma et al. in 2008 successfully provided a direct link between the
dysregulation of c-Met signaling and the development of tumors in human patients (31).
The degradation of the extracellular matrix (ECM) surrounding the tumor cell is a
major milestone on the road to metastasis (32). Tumor cells are capable of releasing
enzymes known as proteases that are capable of hydrolyzing peptide bonds in order to
break down the ECM (32). Also crucial to the metastasis of cancer is the formation of
invadopodia within the cytosol (32). Similar to lamellipodia, invadopodia are actin-rich
cytoskeletal structures that are mediated by intracellular components such as focal
adhesion kinase (FAK), paxillin, cdc42 and Rac1 (32). cdc42 and Rac1 are both members
of the Rho GTPase family, which has been shown to promote the formation of
lamellipodia and invadopodia (32). Rac1 is required for the formation of cell protrusions
in both collectively and individually migrating cells (33). To degrade the ECM and
invade new tissue, tumor cells must coordinate their actions with one another. Cell-to-cell
communication is crucial to the development of invadopodia and lamellipodia by
restricting the formation of protrusions to the leading cell (33). A lack of this
communication between cells results in a chaotic disorganization that hinders the tumor
cells’ ability to organize their cytoskeletons to complement one another (33). cdc42 plays
a major role in the cell-to-cell communication associated with the collective movement of
migrating cancer cells (33). The c-Met signaling pathway stimulates the activation of the
Ras pathway. The subsequent activation of Rac1/Rho/cdc42 leads to the reorganization of
the cytoskeleton needed to form cellular structures needed for invasion and migration.
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c-Met Activation of Rac1/Rho/cdc42 Necessary for Cell Migration
More recent studies have supported the hypothesis that CD82 is interfering with
the integrin crosstalk responsible for the C-Met signaling pathway, but they have yet to
identify the exact point in the pathway that CD82 is targeting. The re-expression of CD82
does not alter the activation of ERK (extracellular signal-regulated kinase), or AKT
(RAC-alpha serine/threonine-protein kinase), which narrows down the list of possible
targets for CD82 (24). The specific target this publication focuses on is the
Rac1/Rho/cdc42 pathway. When the c-Met signaling cascade begins, growth factor
receptor-bound protein 2 (Grb2) forms a complex with son of sevenless (SOS). After the
complex has forms, the next step is the activation of Ras, which in turn activates the
Rac1/Rho/cdc42 step. The end result of the activation of these proteins is actin
cytoskeleton arrangement and changes in cell motility. Rac1 is a small GTPase that is
involved in cell migration, cell cycle progression, and cytoskeleton arrangement (34).
Specifically, Rac1 aids in the formation of lamellipodia and membrane ruffling (34).
Lamellipodia formation can be is the first step in the cytoskeletal rearrangement required
for migration; the actin fibers within the cell begin to extend through the cell lamella
region, which is near the front of mobile cells (34).

Metastatic Signaling by c-Met via Rac1 Activation
As mentioned previously, the Rho-family of GTPases has been shown to promote
metastatic growth via cytoskeleton dynamics and cell motility (35). These cellular
activities are tied together with the growth receptor c-Met, the deregulation of which has
been linked to the development of melanoma in mice models (36). The advancement of
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tumors into a metastatic stage is made possible not only through c-Met, but the complex
network of effector molecules that connect c-Met to the cellular controls for migration,
invasion, and cytoskeleton dynamics (37) (26). This signaling network only functions
through the association of c-Met with repulsive co-receptors (plexins), adhesion
molecules such as the α6β4 integrin, and the coordinated actions of the Rho family
GTPases Rac1, Rho, and cdc42 (38) (39) (40).
Recently, a new concept regarding signal transduction maintained by growth
factor receptors has begun to appear in literature. Specifically, there is growing evidence
to suggest that receptors, as well as the adhesion molecules they communicate with, rely
on reactive oxygen species (ROS) and hydrogen peroxide H2O2 as critical intermediate
molecules in the downstream cascade (41) (42). In addition to cytochromes, Rac1 has
been shown to be an important molecular piece of the oxidase complex found in
mammalian cells (43). The Rac1/ROS interaction has been demonstrated to play a role in
mitogenic signaling by PDGF and by oncogenic H-Ras (44) (45) (46). The Rac1/ROS
signaling complex is activated by integrins upon cellular adhesion to the ECM, and is
necessary for the development of proper focal adhesion assembly in NIH-3T3 cells (47)
(48). It is reasonable to assume that the oxidant intermediates generated by Rac1 are
responsible for the metastatic characteristics seen in prostate cancer (49).
The connection between Rho GTPases and the cytoskeleton has been extensively
studied in the neuroblastoma line N1E-115. The activation of Rac1 and cdc42 in these
cells results in the formation of lamellipodia and filopodia along the very edges of the
neurite (50). Despite differences in cell types, the biochemical processes behind the
lamellipodia and filopodia formation rely on the activation of Rho GTPases in to form the
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actin filaments necessary for migration and invasion (50) (51). This relationship carries
over to fibroblasts, neurons, and macrophages (52). The effect of Rho GTPase activation
on the actin cytoskeleton can be observed in epithelial and endothelial tissue, as well as in
circulating cells such as lymphocytes, mast cells, and platelets (53) (54) (55). The effects
of Rho GTPase activation is not limited to rearranging already-present actin filaments;
studies have shown that Rho GTPases, Rac1 plays important regulatory role in
coordinating the cellular activities that rely on the dissembling and re-assembling of actin
fibers (56). Rho activation and signaling is required to form and maintain focal
adhesions, and integrin complexes propagate the movement of the cytoskeleton (57) (58).
With keratinocytes, it has been discovered that both Rac1 and Rho activation are required
for the assembly of the actin cytoskeleton (59).
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Purpose
The focus of this research project was to identify the specific phosphorylation
site(s) and the subsequent signaling pathways in c-Met regulated by CD82. To identify
the specific pathways and to determine the overall role of CD82 in prostate cancer
metastasis, the following objectives were addressed:
1. Identify the c-Met phosphorylation site being blocked by CD82 expression
a. Integrins within the cells were engaged by plating the cells onto a
substrate of collagen or laminin. The cells were then lysed, and the levels
of phosphorylated Met, along with the specific Met phosphorylation sites
(PTyr 1234/1235 and Total Ptyr), were analyzed by gel electrophoresis
and western blot.
2. Determine whether the Rac1 pathway is being regulated by CD82 expression
a. Integrins within the cells were engaged via an adhesion assay. The cells
were then lysed, and the levels of both Rac1 and cdc42 were analyzed by
gel electrophoresis and western blot.
3. Identify the Rac1 induced cellular changes that are being affected by CD82
expression: invasion, migration, adhesion, lamellipodia formation, and F-actin
fiber arrangement.
a. The cells were fixed to a coverslip coated with either collagen or laminin,
and then stained to visualize F-actin fibers and focal adhesions
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Chapter Two: Materials and Methods
Cell Lines and Cell Culture
Human prostate cancer cells (PC3) were obtained from Dr. Cindy Miranti of the
University of Arizona. From this parental cell line, three clones were generated: PC3-5V,
(containing an empty vector), as well as PC3-29 and PC3-#1, both of which express
CD82. The cells were cultured in F12K Media, (Gibco), which was supplemented with
fetal bovine serum (FBS), streptomycin, penicillin, glutamate, and amphotericin B. The
cells were plated in 10mL sterile flasks and kept in an incubator at 37ᵒC with 5% CO2.
Cells not currently being used were flash frozen in liquid nitrogen and stored at -80ᵒC
until they were needed. Frozen cells were quickly thawed in a 37ᵒC water bath, and then
added to a sterile flask with F12K Media (Gibco) at the same temperature. The cells were
then cultured until the flasks were 70-80% confluent, after which further experiments
were performed.

Adhesion Assay
Each cell line was grown until flasks showed 70-80% confluency. Thereafter, the
media was switched to serum-free media, (Gibco, RPMI Medium 1640, Product
No.11875-093), and the cells were grown in this starvation media for an additional 24
hours before beginning the procedure. Substrate plates were also prepared 24 hours in
advance of the procedure. A working stock of 10µg was made of the desired substrate
stock, (1.0 mg/mL laminin or 2.3 mg/mL collagen), and then added to sterile 10mL flasks
in an even layer. Plates were then kept at 4ᵒC overnight. The following day, the
remaining substrate was removed via aspiration, and the plates were washed two times
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with PBS. Once the washes were complete, 1% BSA-PBS solution was added evenly to
each plate. The coated plates were allowed to incubate at 37ᵒC for at least 1 hour.
Approximately 15 minutes into the incubation period of the cells, the BSA solution was
removed and the substrate plates were washed with PBS. The substrate plates were then
incubated upside down to dry until the cells were ready.
For the preparation of the cultured cells, the plates were removed from the
incubator and washed with PBS buffer two times. Once all the PBS had been aspirated, a
1:4 solution of 2X trypsin-EDTA was added to the plates. The plates were allowed to
incubate at 37ᵒC for 10-15 minutes in the 2X trypsin-EDTA solution, or until the majority
of the cells had dislodged. A solution of PBS-EDTA/STI was added to each of the plates
to stop trypsinization. Each cell line was separately pooled into a centrifuge tube and the
plates were washed twice more with the same solution (PBS-EDTA-STI) and pooled
together. The supernatant was discard after centrifugation at 800 rpm for 8 minutes and
the pellet was re-suspended in PBS-EDTA/STI and re-centrifuged. The supernatant was
again removed and the cells resuspended in (without phenol red) DMEM media (Gibco,
DMEM high glucose, Product No.31053-028). The tubes, with caps loosened, were
placed in the 37ᵒC incubator for 30-40 minutes. When the incubation period was
complete, the cells were added to the substrate plates. The plates were incubated at 37ᵒC,
checking every 15 minutes for adhesion under a microscope. Meanwhile, the cell
suspension was centrifuged and the supernatant removed. Lysis buffer (RIPA or MAPK)
was added and the plates were kept on ice for 30 minutes. Once all of the plates
developed signs of cell adhesion (actin projections, flattened appearance, etc.), the plates
were removed from the incubator and carefully aspirated to remove any free-floating

34

cells. The same lysis buffer added to the suspension was also added to the substrate
plates. After adding the lysis buffer, the plates were immediately placed on ice until all
plates had been coated in the buffer. For the lysis to take place, the plates were placed at
4ᵒC for at least 30 minutes. After the lysis had taken place, the cells were removed using
a cell scraper and then transferred to a microfuge tube. The samples were centrifuged,
including the cell suspensions, at maximum speed for 5 minutes at 4ᵒC. Once the samples
had been collected, a BCA protein assay (ThermoFisher Scientific, Catalog No. 23225)
was performed to determine the concentration of protein in each of the samples. All
unused samples were stored at -80ᵒC.

BCA Protein Assay
On the day of the immunoprecipitation assay, all samples were removed from the
-80ᵒC environment. The samples were centrifuged at maximum speed for two minutes at
4ᵒC. Keeping all reagents and samples on ice, a protein assay was performed using the
PierceTM BCA Protein Assay Kit (ThermoFisher Scientific, Catalog No. 23225). Protein
standards were prepared using the BCA protein solution provided in the kit. Exactly
10µL of each sample was added to 40µL of distilled water; 1mL of the mixed Reagent A
and Reagent B was added after the samples had been thoroughly mixed. The solution was
also added to the protein standards. The samples and standards were incubated in a 37ᵒC
water bath for 30 minutes. After the incubation period was complete, the absorbance of
each sample was measured at 562 nm. This calculation allowed for the concentration of
protein to be determined in each of the samples.
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Immunoprecipitation Assay
Protein A-agarose beads (Pierce, Product No.20333), were prepared by washing
the beads three times with 1% BSA in lysis buffer. In between the washes, the beads were
placed in the centrifuge and spun at max speed for two minutes at 4ᵒC. The cell samples
were thawed and prepared for the assay by making a concentration of 1 ug/uL in the same
lysis buffer as used above, then stored on ice until the primary antibody was added. After
the primary antibody was added, the samples were left on the rotator at 4ᵒC overnight.
The beads were then washed three times with the lysis buffer, spinning at 4ᵒC for two
minutes in between each wash. The supernatant was then removed and the beads
resuspended in 2X SDS buffer (800 uL of 2X sample buffer and 200 uL of betamercaptoethanol). The samples were boiled for five minutes, and then spun for two
minutes at maximum speed at room temperature. The supernatant was then removed and
added onto an SDS-gel (sodium dodecyl sulfate with distilled water ) and the proteins
separated by electrophoresis.
Table 1: Targets for immunostaining are given with their corresponding antibody, as well as the
dilution that was used to achieve optimal results.
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Western blots
A polyacrylamide gel was loaded with equal concentrations of protein for each of
the desired samples. In addition to each of the samples, a prestained molecular weight
marker (Novex Benchmark ™ Prestained Protein Ladder, Product No.10748-010) was
loaded as well. SDS running buffer was added to the gel apparatus prior to the loading
and running of the gel. The gel was run at 125V for 90 minutes, or until the samples had
migrated ¾ of the length of the gel.
Once the gel had been run to completion, it was then blotted to a PVDF
(polyvinylidene fluoride) membrane (Immobilon Transfer Membrane, Product No.
IPFL07810). This was accomplished by placing the electrophoresis gel into a transfer
tank for 3 hours at 25V using blot transfer buffer. The transfer buffer used for western
blotting was Novex Tris-Glycine Transfer (ThermoFisher Scientific, Catalog No.
LC3675) buffer plus methanol, and distilled water. When the gel had been blotted, any
potential non-specific binding sites were blocked with 5% BSA/TBST and incubated for
2 hours at room temperature. The appropriate primary antibody was added to the blotting
membrane (see Table 3), then incubated at room temperature for 2 hours. The blot was
then washed four times with wash buffer (.1% PBS-2.0 Tween), spending 10 minutes on
the shaker between each wash. After the final wash, the secondary antibody, (Li-Cor
IRDye 800CW; donkey-anti-mouse Product No. 926-32212, or donkey-anti-rabbit
Product No.926-32213), was then added to the membrane, which was allowed to rotate
for one hour. The blot was again washed four times with the wash buffer, shaking 10
minutes in between each wash. The blot was illuminated at 800nm and imaged was
captured using the Li-Cor Odyssey Imaging Suite (LI-COR Biosciences, Lincoln NE). In
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the case of fixed cells, an adhesion assay was carried out on an endogenous matrix of
either collagen or laminin. Once the cells were fixed and permeabilized they were stained
for the appropriate targets.

Immunostaining
In order to carry out the immunostaining necessary to view cytoskeletal
components, a “mini” adhesion assay must first be carried out. Rather than transferring
the starved cells to plates that have been coated in collagen, cover slips must be prepared
instead to visualize the cytoskeleton. Single cover slips were placed in a six well plate,
and washed three times with 70% ethanol, followed by washing three times with PBS.
After being coated with a 10µg solution of collagen, the cover slips were allowed to
incubate at 4ᵒC overnight. On the day of the assay, the cover slips were washed twice
with PBS and then blocked with a 1% BSA in PBS. The plates containing the starvation
media and the cells were prepared according to the adhesion assay protocol up until the
point at which they were added to the collagen coated plates. The cover slips were
washed two times with PBS, and then kept at 37ᵒC for five minutes to dry. Once the cells
had been allowed to incubate for roughly 30-40 minutes in clear DMEM medium,
approximately 1mL of cell suspension was added to each of the cover slips. The
coverslips were then placed in the incubator at 37ᵒC until adhesion was observed,
approximately for one hour. Cells were fixed with 2% paraformaldehyde for 20 minutes
at room temperature. The fixed cells were washed three times with PBS. Once the
remaining PBS had been removed, the cells were permeabalized with 0.1% Triton in PBS
and left at room temperature for three to five minutes. The permeabilized cells were then
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washed three to four times in PBS. The slides were blocked with 0.1% BSA in PBS for
two hours at room temperature, after which they were washed three times with PBS. The
cover slips were then carefully transferred from the six-well plates to a plastic tray lined
with parafilm. Table 4 shows the immunostaining targets with their appropriate primary
and secondary antibodies with the correct dilution in PBS with 1% BSA and incubation
period. Before the addition of each antibody, cells were washed three times with 0.1%
BSA, 0.05% Tween 20 in PBS. The washes lasted approximately 10 minutes each. After
the secondary antibody had been washed off, the cover slips were once again washed
three times with 18 MΏ water and carefully dried. A drop of anti-fade reagent
(ThermoFisher Scientific, ProLong Antifade Reagent, Product No. P36930) was added to
each slide and the cover slip was inverted on top of it. The slides and cover slips were
sealed together using clear nail polish and stored in a dark environment at 4ᵒC overnight.
Images of the slides were captured using the Olympus BX51 Upright Compound
Microscope, with a QImaging Retiga 2000R FAST1394 camera.

Table 2: Immunostaining targets with corresponding primary and secondary antibodies. Dilutions
and incubation times and temperatures are given for each individual target.
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Chapter Three: Results
c-Met Activation is Dependent on CD82 Expression
Before the levels of c-Met were measured and compared across cell lines, the
expression of CD82 in the PC3-#1 and the PC3-29 cell lines needed to be confirmed. An
adhesion assay was carried out, and the CD82 protein was immunoprecipitated from all
three experimental cell lines. CD82 produces a broad band centered at approximately 37
kDa. The PC3-5V do not show evidence of this band, while there is a dark band visible in
the PC3-#1 and PC3-29 lanes (Figure 3). This indicates that the cell lines containing the
CD82 vector were expressing CD82 as expected.
To confirm that each of the three cell lines expressed c-Met under our growth
conditions, an adhesion assay was carried out. Using collagen as the substrate, both the
suspension and collected lysates of the samples were transferred to a PVDF membrane
and stained for total c-Met expression. This includes both the phosphorylated, active form
of c-Met, and the unprocessed c-Met. The cell suspensions do not show signs of activated
proteins (Figure 4). Without any matrix to adhere to, there is no signaling through
integrins. When the cell adheres to a matrix, such as laminin, the amount of signaling
increases. The substrates used in this study were collagen and laminin. There is a higher
concentration of both forms of the c-Met protein in the sample from the PC3-5V cell line.
The blot seen in Figure 4 was stripped of primary and secondary antibodies, and
then was stained for total c-Met concentration, rather than total Ptyr. All of the cell lines
show equal concentrations of total c-Met (Figure 5). As mentioned above, CD82 has not
been found to interfere with the overall concentration of c-Met. The levels of functional
c-Met are not dependent on the levels of CD82 found in the cell. The data does
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demonstrate that CD82 is affecting c-Met activation; cells expressing CD82 have lower
levels of activated c-Met. The levels of phosphorylated proteins appear to decrease when
CD82 is returned to physiological levels, demonstrating that CD82 is interfering with
integrin crosstalk.

Figure 3: Western blot demonstrating the expression of CD82 in the
experimental cell lines. Suspensions of all three cells lines were lysed
and the CD82 protein immunoprecipitated. The protein was transferred
to a PVDF membrane for western blotting. The blot was visualized at
800nm using a Licor Imaging System. The 5V cell line carries only an
empty vector, and does not express CD82. Both PC3-#1 and PC3-29
cells have vectors that contain functional CD82.

Figure 4: Western blot depicting the activation of processed c-Met in the experimental cell lines with
laminin as a substrate and a PTyr probe. Cells were allowed to adhere to an endogenous matrix until
adhesion was observed. Lysates were collected and kept frozen at -80ᵒC until use. Lysates were also
collected from suspensions of each cell line to serve as a control. Protein was analyzed via western
blot, and stained with 4G10® Platinum, Anti-Phosphotyrosine, Millipore, Product No. 05-1050.
5VL-PC3 cell line engineered with an empty vector, adhered to the endogenous matrix laminin; 5VSPC3 cell line engineered with an empty vector, sample collected from cell suspension for control;
29L- PC3 cell line engineered with a CD82-expressing vector, adhered to the endogenous matrix
laminin; 29S- PC3 cell line engineered with a CD82-expressing vector, sample collected from cell
suspension for control. The reduced intensity of the processed c-Met band is indicative of reduced cMet activation in the PC3-29 cells.
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Figure 5: Western blot depicting the total c-Met found in each of the samples, with laminin as a substrate.
Cells were allowed to adhere to an endogenous matrix until adhesion was observed. Lysates were collected
and kept frozen at -80ᵒC until use. Lysates were also collected from suspensions of each cell lines to serve as
a control. Protein was analyzed via western blot, and stained with c-28 c-Met (Santa Cruz Biotechnology,
Product No. sc-161). “S” indicates a cell suspension, which serves as a negative control. “L” indicates an
adhered cell lysate with laminin as a substrate.

Phosphorylation Levels of Tyr1234 and Tyr1235 Are Not Dependent on CD82
Expression in Experimental Cell Lines
One of the most common hypotheses regarding the interaction of CD82 and c-Met
is that CD82 interferes with the phosphorylation of the four sites located at the base of the
intercellular portion of the growth receptor. To test this hypothesis, an
immunoprecipitation technique was carried out to analyze the expression levels of the
activated phosphorylation sites Tyr1234 and Tyr1235 (Figure 6). Analysis of the
resulting western blot revealed similar levels of phosphorylated protein between the two
experimental cell lines.

42

Figure 6: Expression levels of phosphorylated Tyr1234 and Tyr1235. These two phosphorylation sites
are located on the intercellular portion of the c-Met receptor, and begin the signaling cascade that
eventually leads to Rac1 activation. The levels of PTyr1234 and PTyr 1235 remain constant despite
CD82 expression. “S” indicates a cell suspension, which serves as a negative control. “CL” indicates an
adhered cell lysate with collagen as a substrate.

cdc42 Expression Remains Unchanged in the Presence of CD82 Expression in
Experimental Cell Line
cdc42 is a small GTPase with functions that are similar to those of Rac1, and
whose location in the c-Met signaling pathway are predicted to be the same.
Immunoprecipitation was carried out to isolate only the activated cdc42 from the sample
lysates, and the protein was visualized via western blotting. A positive cdc42 cell lysate
with a His tag attached and a cdc42 cell lysate without the His tag served as positive
controls. The levels of activated cdc42 appear to be unchanged, both between and within
the cell lines (Figure 7). However, the presence of a faint band in the negative control
indicates that a follow-up assay may be necessary. To confirm the results seen in the
cdc42 assay, a simplified western blotting procedure, (immunoprecipitating the target
protein from only the cell suspensions), was carried out to visualize the levels of
activated cdc42 protein in only the cell suspension samples (Figure 8). The levels of
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activated cdc42 protein appear to be independent of CD82 expression, as the cell
suspensions and lysates all display comparable levels of the protein.

Figure 7: cdc42 activation assay results showing the expression levels of recombinant cdc42-His, (i.e. the
positive control with His tag added for identification) and endogenous cdc42 found naturally in the cell
lines. Lysates from both cell suspensions and adhesion assays were used to analyze the levels of cdc42
present in the cells, with the cell suspensions serving as a control. The levels of cdc42 remain constant in
the presence and absence of CD82 expression. Lane borders have been added by the author for clarity.

Figure 8: cdc42 assay results showing the expression levels of endogenous cdc42 in its activated form,
using only cell suspensions. Results from the previous assay have been simplified to show the levels of
activated cdc42 found in the suspensions in the experimental cell lines. The levels of activated cdc42 are
comparable across the three different cell lines.
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Correlation of Rac1 Activation With CD82 Expression
A Rac1 assay was used to isolate the activated form of the Rac1 protein from
cellular suspesions. Cell suspensions were collected from each of the three cell lines, and
the activated Rac1 protein was isolated from each of the samples. The isolated protein
was visualized using standard western blotting techniques. Analysis of the protein levels
showed higher expression levels of activated Rac1 protein in the PC3-5V suspension
sample, which does not express CD82 (Figure 9). The PC3-29 and PC3-#1 cell lines both
express CD82, and these cell lines showed lower levels of activated Rac1 protein than the
PC3-5V suspension sample.

Figure 9: Rac1 assay results showing the expression levels of Rac1 in its activated form in a pull-down
Rac1 assay using cell suspensions. The western blot show the levels of activated Rac1 found in the
suspensions in all of the experimental cell lines. The levels of activated Rac1 appear to be elevated in the
5VS sample, which does not express CD82.

Visualization of CD82 Expression in Experimental Cell Lines
The PC3-5V cell line contains an empty vector, and does not express CD82. To
validate the findings of the c-Met and PTyr activation assays, cell staining was carried
out to identify which cells were actively expressing CD82. If the activation of c-Met was
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truly being influenced by the expression of CD82, there would be observable changes in
the cytoskeleton. Part of the c-Met signaling pathway includes signaling migration and
cytoskeletal rearrangement, mediated by Rac1 activation. If the express of CD82 is
interfering with the activation of either of these proteins, there will be observable
characteristics. Figure 10B demonstrates the results of the immunofluorescent staining of
PC3-29 cells for CD82 expression. The staining pattern indicates that CD82 is being
expressed across the cell membrane, with little fluorescence visible within the cell itself.
Figure 10A shows the result of CD82 staining for the PC3-5V cells. Little to no
fluorescence is visible, within the cytosol or on the cell membrane, indicating a lack of
CD82 expression in the PC3-5V cell line. When it had had been experimentally validated
that the PC3-29 cells were expressing CD82, the next step was to evaluate cytoskeleton
changes.

A

B

Figure 10: Visualization of CD82 in experimental cell lines. A) PC3-5V cells were treated with antiCD82 antibody [TS82b] Abcam Product No. ab59509. PC3-5V have been transfected with an empty
vector, and thus do not express CD82 on the surface. B) PC3-29 cells were treated with anti-CD82
antibody [TS82b] Abcam Product No. ab59509. PC3-29 have been engineered with a vector that
contains the CD82 expression system. Areas of CD82 expression have been highlighted on the surface
of the cell.
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Visualization of F-actin Stress Fibers in Experimental Cell Lines
A comparison was made between the actin cytoskeleton arrangement in the
presence and absence of CD82 expression. This was done by staining the cytoskeleton
using rhodamine phalloidin to locate F-actin within the cell. Figure 13 depicts the results
of staining PC3-29 cells with rhodamine phalloidin to visualize the location of F-actin
fibers, polmerized actin, and stress fibers within the cell. The irregular surface of the cell
indicates that it has begun to adhere to the endogenous matrix on the cover slip; however,
there is no evidence of F-actin on the outer edges of the cell. There is a limited amount of
fluorescence that can be seen towards the center of the cell, but there does not appear to
be any signifcant structural arrangement. In contrast, Figure 11 shows F-actin fibers
scattered throughout the cytosol, and is of a higher intensity in the than the PC3-29 cells.

A

B

Figure 11: Visualization of F-actin fiber arrangement in experimental cell lines. Both cell lines were
stained with rhodamine phalloidin to highlight the location of F-actin fibers and focal adhesions with
the cell and on the cellular membrane. A) Rhodamine phalloidin staining of PC3-5V cells. F-actin
fibers are visible throughout the entire cytosol, with evidence of focal adhesions forming within the
cytosol. In the far right micrograph, the cytoskeleton has arranged the F-actin fibers such that the cell
has formed lammellipodia in preparation for migration. B) Rhodamine phalloidin staining of PC3-29
cells. The F-actin fibers are concentrated in the center of the cytosol, as well as on the edges. Focal
adhesions have formed on the edges of the cell membrane indicating the adhesion of the cell to the
extracellular matrix. Projections are visible along the extracellular membrane as the cell adheres to the
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Chapter Four: Discussion
The metastasis of malignant tumors is the leading cause of mortality amongst
cancer patients (32). Prostate cancer shows a high affinity for metastasis to both brain and
bone tissue as it progresses to more advanced stages. Metastasis is made possible by two
factors: the degradation of the extracellular matrix, and the remodeling of the actin
cytoskeleton. In order for the cells in the primary tumor site to migrate to other tissues,
they must make their way through the basement membrane and into underlying blood
vessels. Tumor cells are capable of producing matrix metalloproteins, such as MMP-2,
MMP-9, and plasmin, to break down the extracellular matrix (60). When the extracellular
matrix has sufficiently degraded, tumor cells can pass through the basement membrane
and into blood vessels through a process known as intravasation (60).
The movement of the tumor cells across the matrix and between the cells lining
the blood vessels is aided by the arrangement of the actin cytoskeleton. F-actin fibers
within the cytosol can be arranged to form invasive structures such as lamellipodia and
filipodia. These invasive projections can be extended from the main cell body, and when
the cytoskeleton contracts, the cell will migrate across the matrix. The cytoskeleton can
also be arranged to allow the cell to pass between the tightly connected cells forming the
blood vessels. Actin fibers will gather along the edges of the cell to prepare for
lamellipodia formation.
The growth factor receptor c-Met is responsible for a signaling cascade that
results in the promotion of metastatic characteristics. These characteristics include
invasion, migration, proliferation, cell survival, and cytoskeleton rearrangement (Figure
12). In 2006, a study conducted by Sridhar and Miranti demonstrated that the tumor
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suppressor protein CD82 is able to regulate c-Met activation in the metastatic prostate
cancer cell line PC3 (5). Both CD82 and c-Met expression is heavily regulated in normal
cells. When uncontrolled cell growth progresses to cancer, the downregulation of CD82
is observed in a variety of cancer types, including prostate cancer (5). Metastatic prostate
cancer has also demonstrated an overexpression of c-Met (5). When CD82 is restored to
physiological levels in metastatic prostate cancer cells, the result is a decrease in
observable metastatic characteristics and the deactivation of important signaling proteins
(5).
Structure and Function of c-Met
The ability to identify proteins and/or signaling molecules involved in prostate
cancer metastasis would open up an entirely new area of research into drug therapeutics.
One potential drug target is the c-Met signaling pathway, which has been shown to be
involved in cancer cell migration and invasion (3). c-Met is a member of the tyrosine
kinase receptor family, and is found bound in the cellular membrane (29). The receptor is
composed of two subunits, α and β, that are linked to one another via a disulfide bond
(29). The β chain is made up of three regions: an extracellular domain, a transmembrane
region, and cytoplasmic region that extends through the membrane and into the cell itself
(29). The pathway begins by the binding of the ligand, hepatocyte growth factor (HGF),
to the membrane-bound receptor on the outside of the cell membrane. c-Met can also be
activated by integrin signaling within the cell as well. Elevated levels of these integrins
are associated with tumor formation and metastasis (5). The binding of HGF to the c-Met
receptor activates the kinase function of the protein, which dimerizes and phosphorylates
two tyrosine residues at the two key phosphorylation sites this project explored (Tyr 1234
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and Tyr 1235) (29). The activation of the c-Met receptor results in the phosphorylation of
four key sites within the cytosol. The phosphorylation of these four sites then sets off a
signaling cascade, with each subsequent molecule activating the next. When the cascade
has been triggered, a docking site forms via the phosphorylation of two more tyrosine
molecules, Tyr 1349 and Tyr 1356. The site is located on the C-terminal tail, and when
the site is phosphorylated the tyrosine molecules recruit downstream effector molecules
(61). These major signal relay molecules include Src, growth factor receptor bound
protein 2 (GRB2), GRB2-associated binding protein 1 (GAB1), phosphoinositide-3kinase (PI3K), SHC, SHP2, and signal transducer and activator of transcription 3
(STAT3) (61) (29). The end result of this cascade is the stimulation of cellular activities
associated with metastasis, including dissociation, migration, invasion, and cytoskeletal
rearrangement.
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Figure 12: Extended diagram showing the full c-Met signaling pathway. The binding of hepatocyte growth
factor (HGF) leads to the phosphorylation of four key sites within the cytosol, which initiates a signaling cascade
that stimulates cellular activities associated with tumor metastasis, such as dissociation, migration, invasion, and
cytoskeletal rearrangement.

Regulation of c-Met Downstream Signaling by CD82
The first objective of this study was to identify the phosphorylation site being
regulated by CD82 expression. The levels of activated c-Met have been shown to be
dependent on the expression of CD82 in the experimental cell lines, both in previous
research and in this study (Figure 4) (5). The PC3-5V, which do not express CD82, have
significantly higher levels of activated c-Met in the sample. The c-Met protein was
isolated from cell suspensions and adhered cell lysates, and then treated with a PTyr
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probe. This probe is used to highlight the presence of phosphorylated proteins. The use of
the PTyr probe assumes the phosphorylation of c-Met is equivalent with activation. There
is a higher concentration of phosphorylated proteins in the cell line that is lacking CD82
expression. This is demonstrated by the increased band intensity at 140 kDa in the 5VL
sample (Figure 4). Integrin signaling is silenced when the cells are not adhered to a
matrix. The cell suspensions do not show any evidence of activated c-Met. The levels of
activated c-Met appear to decrease in the presence of CD82 expression in PC3 cell lines
(Figure 4).
While CD82 may play a role in the regulation of c-Met activation, it does not
appear to affect the overall expression of c-Met (Figure 5). The levels of total c-Met
present in the cell lines was observed using a total Met probe. There is an important
distinction that must be made between the probe used to observe total c-Met and the PTyr
probe. As mentioned previously, the PTyr probe is used to look at phosphorylated
proteins that have been isolated from samples using immunoprecipitation. The total Met
probe also requires immunoprecipitation, but it cannot differentiate between active and
inactive c-Met. Therefore, the results of the total c-Met western blot cannot be used to
draw conclusions regarding the activated state of c-Met. The levels of total c-Met do not
appear to change in the presence of CD82 expression (Figure 5). The 140 kDa band
produced by the total Met probe does not lose intensity between the PC3-5V and PC3-29
cell lines (Figure 5). This indicates that the production of c-Met is not dependent on
CD82 expression, but CD82 does appears to be regulating c-Met activation.
This research project was successful at demonstrating that the expression of the
tumor suppressor protein CD82 is regulating the activation of c-Met without influencing
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the overall production of c-Met. The relationship between CD82 expression and c-Met
observed in this study is supported by previous literature (5). An interesting question
posed by these results is if this relationship would prove to be true across different types
of extracellular matrix proteins. Laminin was used to look at the activation of c-Met,
while collagen was used to investigate the PTyr 1234/1235 phosphorylation site. There
was no noticeable change in the level of phosphorylation between the different cell lines.
Further research would include using both laminin and collagen for the PTyr 1234/1235
phosphorylation sites. For example, in addition to exploring PC3 cellular adhesion to
collagen, laminin, and fibronectin, further research could be done using attachment factor
protein matrix. This matrix contains gelatin as an attachment factor, and enhances the
growth of endothelial cells. If the starved cells are placed on a surface that has been
coated with an attachment factor, it is possible that even cells displaying migratory
characteristics would demonstrate higher levels of attachment. An increase in the binding
affinity of the cell to the substrate could have an observable effect on metastatic
characteristics, as well as the levels of activated c-Met found in the cells.

Regulation of c-Met Phosphorylation by CD82
The second objective of this study was to identify the specific c-Met
phosphorylation site being regulated by CD82 in PC3 cells. A special focus was placed
on the Tyr1234/1235 phosphorylation site. This is one of four sites that become
phosphorylated once c-Met is activated by the binding of HGF or integrin activation.
Tyr1234/1235 was chosen due to previous research showing that AKT and ERK are not
affected by CD82 expression in PC3 cells (5). The activation of AKT and ERK can be
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traced to their respective phosphorylation sites, neither of which includes the
Tyr1234/1235 site. Preliminary data suggest that CD82 does not affect the
phosphorylation of the other three sites, indicating that the activation of Tyr1234/1235
could be dependent on CD82 expression. This possible relationship was explored by
immunoprecipitating c-Met, isolating Tyr1234/1235 from the cell lysates and probing for
phosphorylated proteins. The phosphorylated version of Tyr1234/1235 creates a band at
approximately 140kDa when run through an SDS-PAGE gel. There is a distinct band
visible at 140 kDa in both the experimental and control cells, indicating the presence of
phosphorylated Tyr1234/1235 protein (Figure 6). The intensity of this band remains
constant across the four sample lanes. There does not appear to be any differential
phosphorylation amongst the cell lines. The expression of CD82 does not seem to have
an effect in the phosphorylation of the Tyr1234/1235 site.
From the data collected by this project, it can be determined that the
phosphorylation of Tyr1234/1235 site was not affected by CD82 expression. However,
this study was unsuccessful at determining which c-Met phosphorylation site is being
regulated by CD82. If the phosphorylation of the Tyr1234/1235 site is not being
regulated by the expression of CD82, the question remains as to which site is being
regulated by CD82 expression. Considering the preliminary studies mentioned at the
beginning of this section, it suggests the question if the phosphorylation of the four key
sites is being affected by CD82 expression. In non-small cell lung carcinoma and oral
squamous cell carcinoma, CD82 was found to attenuate the association between c-Met
and several adaptor molecules, such as Grb2 and p85 (62). The arrangement of the actin
cytoskeleton observed when CD82 is expressed suggests that CD82 is interfering with
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migratory signaling. Cell migration is a complex phenomenon that is regulated by
adaptor proteins, which recruit GTP-binding proteins cdc42, Rho, and Rac1 (62). Rather
than interfere with the phosphorylation of the initial four sites, it is plausible that CD82 is
instead regulating the recruitment of adaptor proteins. This hypothesis could be validated
by observing the levels of adaptor proteins such as p85 and Grb2, which are responsible
for activating cdc42 and Rac1, in each of the experimental cell lines. If CD82 expression
is associated with lower levels of adaptor proteins, it would provide an explanation as to
why the phosphorylation of the four key sites in c-Met remain unchanged in the presence
of CD82.

CD82 Expression Regulates Downstream Signaling Events in the c-Met Signaling
Pathway
The decision to explore the relationship between CD82 expression and Rac1
activation was influenced by previous research. As mentioned before, a study published
in 2006 demonstrated that the ERK and AKT pathways were not influenced by CD82
expression in PC3 cells (5). Even if CD82 was interfering upstream in these two
pathways, it would still not have the observed impact on migration and invasion
characteristics. The activation of ERK is required for cell proliferation, and AKT
activation leads to the development of survival characteristics in prostate cancer cells.
Previous research conducted in our lab showed that the expression of CD82 in prostate
cancer led to observable effects in the arrangement of the actin cytoskeleton. The ability
of CD82 to influence the formation of F-actin fibers, polymerized actin, and stress fibers
and their arrangement suggests that CD82 is interfering with a portion of the c-Met
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signaling pathway involved in cell motility. Rac1 is a small Rho GTPase that is involved
in cell motility and actin cytoskeleton reorganization (Figure 12). The role of Rac1 in the
recruitment of F-actin fibers and chemotaxis has been well documented (63). This makes
an ideal target for CD82 interaction, as the result of Rac1 inactivation is poor cell motility
(63). The protein cdc42 also plays a role in cell migration, and due to its similarity to
Rac1 in size and function, cdc42 activation was investigated.

cdc42 Expression Remains Unchanged in the Presence of CD82 Expression in
Experimental Cell Lines
cdc42 is one of three Rho GTPases that are involved in the c-Met signaling
pathway. Rho GTPases are involved in regulating the dynamics involved in cell adhesion
and the actin cytoskeleton (64). The expression of these GTPases are often altered during
the formation of malignant tumors, but researchers are still working to determine the
exact way they perform their regulatory functions (65). Previous studies have shown that
cdc42 promotes the attachment of cancer cells to endothelial tissue and the basement
membrane by influencing the cells during the transendothelial migration of tumor cells
(65). This invasion strategy is made possible by cdc42 upregulating the expression of the
adhesion receptor known as β1 integrin, a receptor that has already been shown to play a
role in cancer metastasis (66). When cdc42 expression is reduced in metastatic tumor
cells, the cancer cells fail to invade the basement membrane and form attachments to the
surrounding tissue (65).
All three of the PC3 cell lines used in this study are prostate cancer cells derived
from bone metastasis. A cdc42 activation assay was carried out on all three of the cell
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lines, two of which carried a vector containing a function copy of the CD82 gene (PC329 and PC3-#1). The levels of activated cdc42 within the CD82-expressing cells, (PC3#1 and PC3-29), were compared against the levels found in the PC3-5V cells in order to
see if CD82 was interfering with the activation of cdc42. It was found that the level of
activated cdc42 did not vary amongst the three different cell lines, nor did it appear to
vary between adhered lysates and cell suspensions (Figure 8). If CD82 was influencing
the activation of cdc42, there would be higher levels of activated cdc42 in the PC3-5V
cells, both in the suspension and the adhered lysates. Despite its role in cell migration and
invasion in metastatic prostate cancer, our results indicate that cdc42 activation is not
dependent on the expression of a functional CD82 gene (67). It should be noted that a
faint band does appear in the negative control lane. This is most likely due to
experimental error. However, to confidently state the results of the cdc42 assay, the assay
would need to be repeated. The cdc42 activation assay using just the cell lysates does not
display any change in activation in the presence of CD82 expression. This lends evidence
to the hypothesis that the expression of CD82 is interfering with the activation of the
Rac1 protein, which also plays a major role in invasion and migration in the c-Met
signaling pathway.

Rac1 Activation in CD82-Expressing Cell Lines
The activation of Rac1 and related GTPases is required for the assembly and
placement of the actin fibers that make up the cytoskeleton (56). The up-regulation of cMet in prostate cancer correlates with an increase in the activation of downstream
effector molecules, such as Rho, cdc42, and Rac1. It was demonstrated that the levels of
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cdc42 remain constant whether or not CD82 is being expressed by the cell (Figure 8).
This evidence indicates that the decrease in migration seen in the PC3-29 and PC3-#1
cells is not due to CD82 interfering with cdc42. Because there is an observed change in
the arrangement of F-actin fibers in the cytosol, CD82 must be affecting the activation of
the signaling molecule necessary for migration. Rac1 has also been shown to play a role
in the arrangement of the actin cytoskeleton prior to invasion. The isolation of Rac1 from
each of the three experimental cell lines showed a slight increase in the concentration of
activated Rac1 in the PC3-5V cell suspension (Figure 9). PC3-5V does not express
CD82. PC3-#1 and PC3-29, have been engineered to carry a vector with a functional
copy of CD82. The levels of activated Rac1 appear to decrease in the presence of CD82
in cell suspensions. It should be made clear that the decrease in Rac1 activation seen in
this research applies only to the cell suspensions. The cdc42 activation assay was
performed on both adhered cell lysates and cell suspensions. The apparent decrease in
Rac1 activation seen in Figure 9 is only relevant when put into the context of the cell
suspensions. More research is needed to determine if CD82 is involved in the
downstream regulation of Rac1 activation by CD82.

CD82 is Expressed on the Peripheral Cell Surface in PC3-29 Cells
To test for a correlation between CD82 expression and cytoskeletal changes, it
was critical that the expression of CD82 could be visualized in the experimental cell lines
that were engineered to express it. Both cell lines were treated with anti-CD82 antibody
[TS82b] Abcam Product No. ab59509, and visualized using a FIT-C filter under an oilimmersion lens. CD82 is a tumor suppressor protein that is categorized as a tetraspanin
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protein, having four distinct regions that are embedded in the cell membranes of multicellular organisms (18). It is expressed in the cell membranes of all healthy tissues, but its
expression is down-regulated or nonexistent in cancer cells, particularly in prostate
cancer cells (7). PC3-5V showed little to no evidence of CD82 expression on the cell
surface (Figure 10A). Even when the contrast of the micrographs was enhanced, there
was no sign of CD82 expression at the cell surface in the PC3-5V (Figure 10A). In
contrast, the PC3-29 cells showed high levels of CD82 expression (Figure 10B). Much of
the CD82 expression could be seen along the edges of the cell membrane, particularly in
those cells that showed the development of adhesive filaments (Figure 11B).

Lack of CD82 Expression Leads to Invasive Cytoskeletal Changes
Much as the human skeleton supports the structure of the body, the cytoskeleton
supports the structure of the cell body. Changes in the actin cytoskeleton are required for
a cancer cell to metastasizes beyond its native tissue. The remodeling of the cytoskeleton
involves the production and arrangement of polymerized actin, the creation of stress
fibers, and the overall formation of lamellipodia. PC3-5V cells were stained with
rhodamine phalloidin to visualize F-actin fibers and stress fibers. Rhodamine phalloidin
is a high-affinity F-actin probe that can be used to stain for both F-actin fibers and focal
adhesions within the cell and on the cell surface. Staining of PC3-5V show that actin
fibers are visible through the cytosol, with little evidence of focal adhesion formation
(Figure 11A). Adhesive filaments are not visible on the edges of the cell, indicating that
the cell is preparing to migrate. The micrograph on the right shows the formation of
lamellipodia; the cell is beginning to take on a sickle-shaped appearance, and actin fibers
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have begun to congregate along the edge of the cell and the tip of the lamellopodia
(Figure 11A).

CD82 Expression Leads to Development of Adhesion Characteristics
All PC3-29 cells displayed in the micrographs show signs of adhesive filaments
forming around the edge of the cell, indicating that the cell has begun to adhere to the
endogenous matrix (Figure 11B). The F-actin fibers are concentrated in the center of the
cytosol, with a structured scaffolding extended to the edges of the cell (Figure 11B).
Overall, the cytoskeletons of the PC#-29 cells are far more organized than the PC3-5V
cells. The PC3-5V cells do not show signs of adhering to the matrix. They demonstrate
evidence of cellular structures that are associated with invasion and migration. The
difference in the cytoskeletal organization between the two cell lines is assumed to be the
expression of CD82. This lends evidence to the hypothesis that CD82 is interfering with
the c-Met signaling pathway involved in cytoskeletal rearrangement, invasion, and
migration.
In addition to interfering with the activation of Rac1, further research could be
done to investigate other migratory characteristics affected by CD82. Not only would it
be interesting to look at other physical structures, such as F-actin protrusions, levels of Ecadherin could be studied. There is also the possibility that CD82 has a regulatory
function in another pathway involved in cancer cell metastasis, such as fibroblast growth
factor pathways (68). The evidence gained from this study demonstrates no apparent
decrease in cdc42 activation, leading to the hypothesis that CD82 could have other
regulatory roles. In 2015, a study showed that the expression of CD82 reduces the

60

adhesion of cancer cells to blood vessels in Sialyl Lewis antigen-mediated adhesion (8).
It is clear that CD82 has regulatory functions outside of preventing the rearrangement of
the actin cytoskeleton needed for metastasis that are worth investigating.

Overall Conclusions
The results of this study indicated that CD82 has a regulatory effect on c-Met
activation. The overall levels of total c-Met remain unchanged in the presence of CD82,
but the expression of CD82 leads to a decrease in the expression of activated c-Met.
While this project was unable to identify the specific c-Met phosphorylation site being
regulated by CD82, the evidence suggests that the Tyr1234/1235 remains unaffected by
CD82 expression. CD82 does appear to influence downstream events in the c-Met
signaling pathway. We have shown that the levels of cdc42 expression do not change
across the three experimental cell lines, and remain constant in suspension as well. We
investigated the levels of activated Rac1 in cell suspensions, and the levels of activated
Rac1 appear to decrease with CD82 expression. Further research is needed to
conclusively state whether CD82 is influencing the activation of Rac1 in the c-Met
signaling pathway. The results of this study provide evidence to suggest that CD82 is
playing a role in regulating the formation of metastatic characteristics in PC3 cells.
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Chapter Five: Research Summary
This project focused on the role of the metastasis suppressor protein CD82 in the
deactivation of the c-Met signaling pathway in metastatic prostate cancer. Prostate cancer
is currently the second leading cause of death among men in the United States (1). There
are two key players in the metastasis of prostate cancer: tumor suppressor proteins, and
growth factor receptors. Tumor suppressor genes are expressed in normal, healthy cells,
and serve as key regulators of the cell cycle. A mutation in these genes often lead to a
loss or reduction in function, which allows cells to transition into malignant tissues. The
loss of the tumor suppressor protein CD82 has been implicated in approximately 70% of
prostate cancer cases and has been linked to metastasis and poor patient prognosis (69).
Growth factor receptors also play a major role in the regulation of growth signals
in normal cells. The importance of their function means that they are highly regulated in
healthy cells. The overexpression of growth factors has been observed in many different
types of cancer, including prostate cancer. Of the many growth factors, whose
malfunction has been linked to the development of cancer, c-Met is a particularly
attractive target for prostate cancer therapeutics. c-Met has one endogenous ligand:
hepatocyte growth factor (HGF). When HGF binds to the c-Met receptor on the
extracellular surface of the cell, it signals the beginning of a metastatic cascade. This
cascade can also be initiated by engaging integrins. The activation of c-Met leads to the
phosphorylation of four key sites connected to the β-subunit of the c-Met receptor:
pY1003, pY1234/1235, pY1349, and pY1356. The phosphorylation of these four sites
leads to the recruitment of downstream effector molecules that trigger metastatic
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characteristics in prostate cancer such as invasion, migration, cell adhesion, and actin
cytoskeleton re-arrangement (Figure 1).
The first objective in this study was to determine which downstream signaling
pathway found in c-Met was being regulated by CD82. The levels of total c-Met appear
to remain unchanged in the presence of CD82 expression. However, CD82 does appear to
be regulating the activation of c-Met. There are decreased levels of activated c-Met in the
cell lines that are expressing CD82. Overall, this study was successful at concluding that
CD82 expression is regulating the activation of c-met, but not the overall production of cMet.
Identification of the specific c-Met phosphorylation site being regulated by CD82
proved to be rather difficult. The Tyr1234/1235 phosphorylation site was chosen for
investigation due to previous research suggesting the other three sites are unaffected by
CD82 expression. The results of this study indicate that the phosphorylation of the
Tyr1234/1235 site is not regulated by CD82 expression. There is no differential
phosphorylation of Tyr1234/1235 amongst the cell lines used in this study. We were
unsuccessful at determining which c-Met phosphorylation site is being regulated by
CD82, if any. The question does arise as to whether the phosphorylation of these four
sites is being regulated by CD82 expression. Further study is needed to determine which
site, if any, is regulated by CD82.
The final objective of this study was to identify the overall downstream event that
is being regulated by CD82. Previous research showed that the expression of CD82 led to
observable changes in the cytoskeleton of the cell lines. The GTPase known as Rac1 was
investigated as being regulated by CD82 expression. Rac1 is involved in the signaling of
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actin cytoskeleton rearrangement and cell motility. cdc42 is a protein of similar size and
function to Rac1, and the effect of CD82 expression on cdc42 was also investigated. The
levels of activated cdc42 appear to be unchanged in the presence of CD82. Levels of
activated Rac1 in the cell suspensions appeared to decrease with CD82 expression. While
the suspensions appear to indicate an inverse relationship between Rac1 activation and
CD82 expression, the results remain inconclusive. Further research is needed to look at
the levels of activated Rac1 in both cell suspensions and adhered cell lysates. The
expression of CD82 also appears to the lead to the development of adhesion
characteristics. PC3-29 cells demonstrated the formation of actin projections that suggest
adherence to the substrate. They also displayed fewer stress fibers and polymerized actin.
The lack of CD82 expression in the PC3-5V cells appears to lead to the development of
invasive cytoskeletal changes. The PC3-5V showed evidence of more stress fibers and
polymerized actin than seen in the PC3-29 cells. PC3-29 cells showed evidence of
adhering to the substrate, whereas the PC3-5V cells demonstrated physical characteristics
that indicate cell migration.
The ability of CD82 to associate with other proteins and regulate their functions is
an important aspect of research into prostate cancer metastasis. The results of this study
indicate that CD82 appears to be regulating the development of migratory characteristics
associated with the activation of the growth factor receptor known as c-Met. Specifically,
CD82 appears to be interacting with the GTPase Rac1, a signaling molecule that has been
shown to have a role in cell motility. Further research is needed to validate the
relationship between CD82 expression and Rac1 activation, but this study provides
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important information regarding the regulatory function of CD82 in prostate cancer
metastasis.
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Chapter Six: Future Directions
While this project represents an investigation into the role of CD82 as an inhibitor
of Rac1 in the c-Met signaling pathway, there still much that remains to be explored. A
more exhaustive analysis of Rac1 activation in prostate cancer cell lines is required to
support the conclusions drawn by this research. Part of this analysis would include
performing a large scale Rac1 activation assay on the three experimental PC3 cell lines.
Rac1 is a very difficult protein to isolate from cell lysates, as it is only expressed for a
limited amount of time while the actin fibers of the cytoskeleton are being rearranged. A
more thorough assay would involve plating multiple plates of the same cell line and
harvesting the lysates from those cells at different time points. This would give more
information as to how long it takes Rac1 to be activated and how long it is expressed in
the presence and absence of CD82. The actual activation of Rac1 could be traced in real
time, and conclusions drawn regarding the effect of CD82 expression on its activation.
Based on the results of this investigation, one would expect to see a decrease in Rac1
activation in the cell lines that express physiological levels of CD82 if it is serving as an
inhibitor (as seen in Figure 9).
Validation of the small-scale assay could then be followed by attempting to
quantify the decrease in Rac1 activation between PC3-29 cell sand PC3-5V cells.
Quantifying the effect that CD82 has on the activation of Rac1 could be instrumental in
developing a more effective inhibitor of Rac1 and related Rho GTPases in the future. The
effect of CD82 expression should also be compared across prostate cancer cell lines, and
potentially across different kinds of human cancers, to see if the inverse relationship
between CD82 expression and Rac1 activation holds true.
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There still are questions to be answered regarding the effect of CD82
expression on the phosphorylation of the four key sites on the c-Met receptor. When
placed in the context of previous research studies, the results of this study suggest that
CD82 does not interfere with the phosphorylation of those four sites. This raises the
question of whether CD82 is interfering with phosphorylation at all. It also demonstrates
a need to investigate if phosphorylation is an adequate method for determining the
activation levels of c-Met.
In addition to observing F-actin fibers, future work could potentially include
observing other invasive characteristics seen in metastatic prostate cancer. This would
include the development of F-actin protrusions and measuring the levels of E-cadherin in
the cells. There is also the possibility that CD82 possess another regulatory function that
has yet to be described. A better understanding of how small Rho GTPases become
inhibited by tumor suppressor proteins such as CD82 could potentially lead to the
development of more effective chemotherapies capable of targeting metastatic
characteristics.
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